Jiangsu Yahong Meditech (SHA:688176) or Asieris Pharmaceuticals signed an investigational drug supply agreement with the US Centers for Disease Control and Prevention for its APL-1202 medication for free-living amoeba infections, according to a Monday press release.

The drug is indicated for free-living amoebae causing amoebic meningoencephalitis, which has a 90% mortality rate, the company said.

The US CDC has also submitted an expanded-access investigational new drug application to the US Food and Drug Administration for the use of APL-1202 in laboratory-confirmed or suspected non-keratitis infections caused by free-living amoeba, Asieris said.

Shares fell 2% during Wednesday's late morning trading.